IQV
IQVIA Holdings Inc.
IQV has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over IQV overall, supported by stronger fundamentals and stronger modeled upside.
IQV Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Weak |
IQV's profitability and cash flow are currently healthy, and its revenue is stable, but its balance sheet is weak.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
IQV PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 20x | $271 | — |
| Cheap | 27x | $218 | -19% |
| Current | 33x | $271 | — |
| Fair | 36x | $292 | +7.6% |
| Expensive | 124x | $1,021 | +277% |
Historical ranges are pointers, not guarantees.
IQV's PE is in its fair range at 33x. If earnings grow as analysts expect, today's price would be 20x next year's earnings, in its cheap range.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over IQV in the historical PE scenario, which offers more potential upside but is not a forecast.
IQV Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for IQV, with profitability holding steady.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over IQV on the outlook, with more favorable profitability expectations.
IQV Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.78 | +68% |
| Q3 2026 | $8.21 | +13% |
| Q2 2026 | $8.04 | +17% |
| Q1 2026 | $8.05 | +9.8% |
| Q4 2025 | $7.84 | +4.7% |
| Q3 2025 | $7.28 | -4.5% |
| Q2 2025 | $6.90 | -10% |
| Q1 2025 | $7.33 | +0.1% |
| Q4 2024 | $7.49 | +2.7% |
IQV has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
IQV Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $4.4B | +8% |
| Q2 2026 | $4.4B | +8.7% |
| Q1 2026 | $4.2B | +8.4% |
| Q4 2025 | $4.4B | +10% |
| Q3 2025 | $4.1B | +5.2% |
| Q2 2025 | $4B | +5.3% |
| Q1 2025 | $3.8B | +2.5% |
| Q4 2024 | $4B | +2.3% |
IQV's revenue has grown year over year every quarter since late 2020: $4.4B last quarter, up 8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 13% | -0.6 points |
| Q2 2026 | 12% | -1 points |
| Q1 2026 | 12% | -0.6 points |
| Q4 2025 | 14% | -1.5 points |
| Q3 2025 | 13% | -0.6 points |
| Q2 2025 | 13% | -1 points |
| Q1 2025 | 13% | -0.6 points |
| Q4 2024 | 16% | +2.9 points |
IQV has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over IQV on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
IQV Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $667M | -14% |
| Q2 2026 | $360M | +23% |
| Q1 2026 | $491M | +15% |
| Q4 2025 | $561M | -22% |
| Q3 2025 | $772M | +35% |
| Q2 2025 | $292M | -34% |
| Q1 2025 | $426M | +13% |
| Q4 2024 | $721M | +27% |
IQV's free cash flow has been positive every quarter for seven years: $2.1B over the past year, down 6% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over IQV on cash flow, with more consistent year-over-year improvement.
IQV Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -300K shares |
| 1 year | -2.7% | -4.7M shares |
| 3 years | -10% | -18.5M shares |
| 5 years | -14% | -28.3M shares |
| Available history | -16% | -32.6M shares |
IQV has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $398M |
| Q1 2026 | $552M |
| Q4 2025 | $212M |
| Q3 2025 | — |
| Q2 2025 | $657M |
| Q1 2025 | $375M |
| Q4 2024 | $1.2B |
IQV spent $1.2B buying back its own shares over the past year, down 47% from the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
IQV Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 4.0x | High |
| Q2 2026 | 4.2x | High |
| Q1 2026 | 4.1x | High |
| Q4 2025 | 4.1x | High |
| Q3 2025 | 4.0x | Elevated |
| Q2 2025 | 4.1x | High |
| Q1 2025 | 3.8x | Elevated |
| Q4 2024 | 3.7x | Elevated |
IQV's net debt is about 4.0 years of its operating earnings (EBITDA), about the same as a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over IQV on leverage, with a lower net debt burden relative to earnings.
IQV Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 65.2 | Neutral |
| Stochastic | 76.5 | Neutral |
IQV's weekly RSI is 65 (neutral) and its Stochastic is 76 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
IQV PE vs Healthcare Sector
| Metric | IQV | Sector median | Relative |
|---|---|---|---|
| PE | 33x | 26x | 28% above |
| PE % | 38 | 29 | 9 pts above |
IQV is trading at 33x earnings, a 28% premium to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over IQV on valuation relative to its sector.
IQV Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $268.1 | 1.1% above |
| 20 week MA | $250.1 | 8.4% above |
| 50 week MA | $213.9 | 27% above |
| 100 week MA | $198.5 | 37% above |
| 200 week MA | $208.6 | 30% above |
IQV has climbed back above all five of its weekly moving averages, and it's now 30% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
IQV Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $154.4 | $175.9 | +14% |
| 2021 | $175.9 | $278.0 | +58% |
| 2022 | $278.0 | $203.8 | -27% |
| 2023 | $203.8 | $231.4 | +14% |
| 2024 | $231.4 | $199.4 | -14% |
| 2025 | $199.4 | $226.9 | +14% |
| 2026 YTD | $226.9 | $271.1 | +19% |
IQV has finished higher in four of the last six years. It's up 19% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over IQV on returns for 2026, with the stronger performance.